Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy Subjects

Phase 1

• Conditions: Rheumatoid Arthritis
• Interventions: Other: Placebo, 10mg; Other: Placebo, 20mg; Biological: GB224 15mg; Biological: GB224 30mg; Biological: GB224 10mg; Other: Placebo, 2mg; Other: Placebo, 5mg; Biological: GB224 2mg; Biological: GB224 5mg; Biological: GB224 20mg; Other: Placebo, 15mg; Other: Placebo, 30mg

• Registration Number: NCT04178070
• Lead Sponsor: Genor Biopharma Co., Ltd.

Brief Summary

The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of single-dose, dose-escalated, abdominal subcutaneous injection of GB224 in Chinese healthy adult subjects. The secondary objectives are to preliminarily understand the immunogenicity and pharmacodynamic variable (IL-6) of single abdominal subcutaneous injection of GB224 in Chinese healthy adult subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-11-06
• Status Verified: 2019-11
• Study First Submitted: 2019-11-24
• Study First Submitted QC: 2019-11-24
• Last Update Submitted: 2019-11-25
• Study First Posted: 2019-11-26
• Last Update Posted: 2019-11-27
• Primary Completion: 2020-12
• Study Completion: 2021-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 58

Inclusion Criteria

1. Understand the study procedures and contents, and voluntarily sign the informed consent form;
2. Chinese healthy adult volunteers aged 18 to 45 years, males and females;
3. The subjects have qualified physical examination within 30 days before the study, the body mass index (BMI) is within the range of 19~24 and the body weight is within the range of 45~75kg;
4. Males or females agree to adopt medically confirmed effective contraceptive measures during the entire study period and within 6 months after the end of this study.
5. The investigator considers that the patients have good health condition according to the physical examination, medical history, vital signs and ECG etc.
6. Patients have good compliance, can receive follow-up visits as scheduled, are able to well communicate with the investigators and complete the study as required by the study.

Exclusion Criteria

1. Any of the following is met: allergic constitution; known allergic to the components of the investigational product or allergy history to any drug or food or pollen; subjects who have medical history of skin allergy such as physical urticaria; subjects who have abnormal serum immunoglobulin E (IgE) test;
2. Any of the current symptoms, signs or laboratory test abnormalities indicating the possible presence of acute or subacute infection (e.g., pyrexia, cough, urgent micturition, urodynia, abdominal pain, diarrhea, cutaneous infected wound etc.)
3. Patients with active pulmonary tuberculosis; patients who previously had medical history of active pulmonary tuberculosis;
4. Subjects who have medical history of drug addiction or drug abuse;
5. Subjects who have clear medical history of central nervous system, cardiovascular, renal, hepatic, gastrointestinal, respiratory, metabolic system or subjects with other significant diseases; subjects with medical history of hypertension or screening systolic blood pressure ≥ 140mmHg and/or diastolic blood pressure ≥ 90mmHg, which are clinically significant at the discretion of the investigators; subjects who have medical history of orthostatic hypotension;
6. Subjects who have medical history of malignant tumors;
7. Subjects who participated in other clinical studies within 3 months before enrollment, or subjects who received drugs which are known to injure the major organs within 3 months before enrollment;
8. Subjects who used prescription drugs or non-prescription drugs within 14 days before enrollment;
9. Subjects who have blood donation history within 3 months before enrollment;
10. Subjects who meet any of the following criteria: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >1.5 times the upper limit of normal (ULN), serum creatinine (Cr) > the upper limit of normal (ULN);
11. Abnormal routine blood tests: any of the following is met: white blood cells (WBC)<3.0×109/L or >9.5×109/L, neutrophil count (ANC)<1.5×109/L, platelet count (PLT)<100×109/L, hemoglobin (HGB)<104g/L;
12. Any of the following is positive: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), acquired immunodeficiency syndrome antibody (Anti-HIV) and anti-treponema pallidum antibody (TP-Ab);
13. Subjects who have positive tuberculosis skin test (5 units of dosage, induration of not less than 5 millimeters (mm) within 48 ~ 72 hours);
14. Subjects with positive anti-nuclear antibody (ANA), anti-double stranded DNA antibody (ds-DNA) and anti-extractable nuclear antigens (ENA);
15. Subjects with positive anti-drug antibody (ADA);
16. Subjects with positive tumor markers (CEA, AFP, PSA and CA-125);
17. Subjects with abnormal coagulation function, which is clinically significant at the discretion of the investigators;
18. Subjects with medical history of psychiatric disorders;
19. Smoking more than 5 cigarettes/day or equivalent tobacco;
20. Weekly alcohol consumption more than 28 units (1 unit = 285 mL of beer or 25 mL of spirits or a glass of wine); or subjects who have positive breath alcohol test within 24 hours before the use of investigational drug;
21. Subjects who have clinically significant abnormal laboratory test values at screening;
22. Female subjects who have positive serum/urine pregnancy tests at screening or lactating women;
23. Patients who have insufficient communication, understanding and cooperation; or patients who have poor compliance and cannot guarantee to strictly follow the study protocol;
24. Subjects who are considered unsuitable for participating in this study for various reasons at the discretion of the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo 10mg	Placebo, 10mg	single dose
Placebo 20mg	Placebo, 20mg	single dose
GB224 15mg	GB224 15mg	single dose
GB224 30mg	GB224 30mg	single dose
GB224 10mg	GB224 10mg	single dose
GB224 30mg	Placebo, 30mg	single dose
Placebo 2mg	Placebo, 2mg	single dose
Placebo 5mg	Placebo, 5mg	single dose
GB224 2mg	GB224 2mg	single dose
GB224 5mg	GB224 5mg	single dose
GB224 20mg	GB224 20mg	single dose
Placebo 15mg	Placebo, 15mg	single dose
Placebo 30mg	Placebo, 30mg	single dose

Primary Outcome Measures

Name	Time	Method
Adeverse Effect, AE	Up to 112 days.	Adeverse Effect, AE
Dose Limited Toxicity, DLT	Up to 112 days.	Dose Limited Toxicity, DLT
Maximum Tolerated Dose, MTD	Up to 112 days.	Maximum Tolerated Dose, MTD
Serious Adeverse Effect, AE	Up to 112 days.	Serious Adeverse Effect, AE

Secondary Outcome Measures

Name	Time	Method
Vd	Up to 112 days.	Vd
Ke	Up to 112 days.	Ke
Mean Retention Time, MRT	Up to 112 days.	Mean Retention Time, MRT
t1/2	Up to 112 days.	t1/2
CL	Up to 112 days.	CL
Tmax	Up to 112 days.	Tmax
Cmax	Up to 112 days.	Cmax
AUC0-t	Up to 112 days.	AUC0-t
AUC0-∞	Up to 112 days.	AUC0-∞

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, Beijing, China